Trial Profile
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Foretinib (Primary)
- Indications Renal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors GSK
- 01 May 2009 Planned end date added as 1 Oct 2009 as reported by ClinicalTrials.gov.
- 01 May 2009 Planned end date added as 1 Oct 2009 as reported by ClinicalTrials.gov.
- 28 Sep 2006 Status change